interrogated the CD161-CLEC2D pathway using a co-culture system with genomic-edited T cells and patient-derived glioma cells to identify CD161 as an inhibitory receptor for tumor-specific T cells (73). This evidence concerns the gene KLRB1 and neoplasm.